Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849788 | 1.00 | KDM1A (0.43) | KDM1AMAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5847722 | 0.87 | MAPK14 (0.48) | KDM1AMAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5849829 | 0.85 | MAPK9 (0.47) | KDM1AMAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5847516 | 0.84 | KDM1A (0.42) | KDM1AMAPK14MAPK13MAPK12 | |
| SCHEMBL5848204 | 0.84 | KDM1A (0.42) | KDM1AMAPK14MAPK13MAPK12 | |
| SCHEMBL5849199 | 0.83 | KDM1A (0.41) | KDM1AMAPK14MAPK13MAPK12 | |
| SCHEMBL5848909 | 0.82 | MAPK11 (0.36) | MAPK11MAPK14MAPK13MAPK12AKT1 | |
| SCHEMBL5849781 | 0.81 | KDM1A (0.45) | KDM1AMAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5847417 | 0.75 | MAPK14 (0.40) | KDM1AMAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL27413911 | 0.74 | KDM1A (0.52) | KDM1AMAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | claimed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | KDM1A 3459/4885MAPK11 1540/4885MAPK14 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.